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Protein products with expression-related manufacturability problems can present a significant barrier to the 
clinical and commercial feasibility of a project. Methods to identify and potentially eliminate poor-expressing 
therapeutic candidates early in the drug development process can simplify process development activities and 
facilitate platform fit, saving resources, costs and time.  Existing experimental methods for screening expression 
level, such as transient transfection or stable pool yields, either lack the capability to accurately discriminate 
between candidates and/or they can be time-consuming, resource-intensive evaluations for multiple candidates. 
An in silico method was investigated with the goal of developing a more efficient and precise screening tool for 
determining expression level of therapeutic candidates. First, a series of homology models were generated for a 
training set of antibodies (i.e. – a set of representative 
antibodies that cover a wide range of stable cell line titers) 
using Molecular Operating Environment (MOE) software [1]. 
Subsequently, MOE was used to obtain a series of 
physicochemical properties for these antibodies. Selected 
properties were then combined into a multiparametric model 
using partial least squares regression. The resultant 
mathematical model demonstrated a robust predictive 
capability using a leave-one-out cross-validation (LOOCV) 
technique (Fig. 1). In addition, the model allowed for 
ascertaining the degrees of contribution of individual computed 
properties to the expression level. The development, 










[1] Molecular Operating Environment (MOE), 2013.08; Chemical Computing Group ULC, 1010 Sherbooke St. 
West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2017. 
 
 
Figure 1 –Plot showing the predicted titers 
estimated using LOOCV versus the 
experimental titer values. 
